NCT07627568RecruitingNot Applicable
Analysis of Biomarkers in Patients With Acute Myeloid Leukemia After Allogeneic Stem Cell Transplantation Treated With Menin Inhibition.
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Recruiting
- Sponsor
- University of Freiburg
- Enrollment
- 20
- Locations
- 1
Study Overview
Brief Summary
The white blood cells of patients with acute myeloid leukemia that have undergone allogeneic stem cell transplantation will be investigated. These are patient where the leukemia has returned after the transplantation.
Detailed Description
The study will investigate biomarkers including humen endogenous retrovirus expression and T cell phenotypic analysis in patients with AML with NPM1 mutations or KMT2A rearrangements. These biomarkers have been previously described: Blood. 2026 Jan 29;147(5):584-601. doi: 10.1182/blood.2025029712. PMID: 41144759
Study Design
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Prospective
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Diagnosis of acute myeloid leukemia with NPM1 mutations or KMT2A rearrangements
- •Hematological relapse after allo-HCT
- •18 years or older
Exclusion Criteria
- •no signed informed consent
Arms & Interventions
AML with NPM1 mutations or KMT2A rearrangements
AML with NPM1 mutations or KMT2A rearrangements that will be treated with immunotherapy (DLI) and immunmodulatory drugs recommended by the guidelines.
Investigators
Robert Zeiser
Professor of Medicine
University of Freiburg
Study Sites (1)
Loading locations...
Similar Trials
Not yet recruiting
Not Applicable
Clinico-hematological and Coagulation Profiles in Newly Diagnosed Acute Myeloid Leukemia Patients Treated With Intensive Induction Chemotherapy .Acute Myeloid LeukemiaNCT07343687Assiut University80
Completed
Not Applicable
Mesenchymal Stem Cells in NPM1 Mutated Low Risk Acute Myeloid Leukemia: a Study of the Tumor Microenvironment and Its Contribution to the OutcomeNCT07379528Fondazione IRCCS Policlinico San Matteo di Pavia70
Recruiting
Phase 1
Efficacy and Safety of Autologous Peptide-induced Active Immunity in AML Maintenance TherapyPersonalized Active ImmunotherapyMaintenance TherapyAcute Myeloid LeukemiaNCT07551037Fujian Medical University Union Hospital90
Unknown
Not Applicable
请于伦理委员会批准后才开始征募参试者，并与我们联系上传伦理批件。 造血免疫功能状态与急性髓系白血病预后相关性的研究急性髓系白血病ChiCTR2100045808自筹60
Unknown
Not Applicable
CLL-1 嵌合抗原受体 T 细胞治疗急性髓系白血病的研发ChiCTR2500100811河南省中青年卫生健康科技创新优青人才培养项目